Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Price:
9.47 USD
-0.84%
Market Closed
Updated:
May 5, 2024
Centessa Pharmaceuticals PLC
Cash from Financing Activities
|
Centessa Pharmaceuticals PLC
Cash from Financing Activities Peer Comparison
Comparables:
EXAI
AUTL
BCYC
IMCR
GNS
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Financing Activities
$21.1m
|
CAGR 3-Years
149%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Cash from Financing Activities
-£3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Financing Activities
-$883k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Financing Activities
$250m
|
CAGR 3-Years
22%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Financing Activities
£34.3m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
221%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash from Financing Activities
-£20.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Centessa Pharmaceuticals PLC's Cash from Financing Activities?
Cash from Financing Activities
21.1m
USD
21.1m
USD
Based on the financial report for Dec 31, 2023, Centessa Pharmaceuticals PLC's Cash from Financing Activities amounts to 21.1m USD.
What is Centessa Pharmaceuticals PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
149%
149%
Over the last year, the Cash from Financing Activities growth was 4 491%. The average annual Cash from Financing Activities growth rates for Centessa Pharmaceuticals PLC have been 149% over the past three years .
You don't have any saved screeners yet
